277 related articles for article (PubMed ID: 28263812)
1. Prognostic effects of rosuvastatin in patients with co-existing chronic obstructive pulmonary disease and chronic heart failure: A sub-analysis of GISSI-HF trial.
Rossi A; Inciardi RM; Rossi A; Temporelli PL; Lucci D; Gonzini L; Marchioli R; Nicolosi GL; Tavazzi L;
Pulm Pharmacol Ther; 2017 Jun; 44():16-23. PubMed ID: 28263812
[TBL] [Abstract][Full Text] [Related]
2. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial.
Tavazzi L; Maggioni AP; Marchioli R; Barlera S; Franzosi MG; Latini R; Lucci D; Nicolosi GL; Porcu M; Tognoni G;
Lancet; 2008 Oct; 372(9645):1231-9. PubMed ID: 18757089
[TBL] [Abstract][Full Text] [Related]
3. Secreted Frizzled Related Protein 3 in Chronic Heart Failure: Analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).
Askevold ET; Gullestad L; Nymo S; Kjekshus J; Yndestad A; Latini R; Cleland JG; McMurray JJ; Aukrust P; Ueland T
PLoS One; 2015; 10(8):e0133970. PubMed ID: 26288364
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Impact of Diabetes and Prediabetes on Survival Outcomes in Patients With Chronic Heart Failure: A Post-Hoc Analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure) Trial.
Dauriz M; Targher G; Temporelli PL; Lucci D; Gonzini L; Nicolosi GL; Marchioli R; Tognoni G; Latini R; Cosmi F; Tavazzi L; Maggioni AP;
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28679559
[TBL] [Abstract][Full Text] [Related]
5. Pentraxin-3 in chronic heart failure: the CORONA and GISSI-HF trials.
Latini R; Gullestad L; Masson S; Nymo SH; Ueland T; Cuccovillo I; Vårdal M; Bottazzi B; Mantovani A; Lucci D; Masuda N; Sudo Y; Wikstrand J; Tognoni G; Aukrust P; Tavazzi L;
Eur J Heart Fail; 2012 Sep; 14(9):992-9. PubMed ID: 22740508
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of elevated serum uric acid levels on long-term outcomes in patients with chronic heart failure: A post-hoc analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure) trial.
Mantovani A; Targher G; Temporelli PL; Lucci D; Gonzini L; Nicolosi GL; Marchioli R; Tognoni G; Latini R; Cosmi F; Tavazzi L; Maggioni AP;
Metabolism; 2018 Jun; 83():205-215. PubMed ID: 29477817
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and Prognostic Impact of Chronic Obstructive Pulmonary Disease in Patients with Chronic Heart Failure: Data from the GISSI-HF Trial.
Canepa M; Temporelli PL; Rossi A; Rossi A; Gonzini L; Nicolosi GL; Staszewsky L; Marchioli R; Maggioni AP; Tavazzi L;
Cardiology; 2017; 136(2):128-137. PubMed ID: 27618363
[TBL] [Abstract][Full Text] [Related]
8. Do statins reduce the risk of myocardial infarction in patients with heart failure? A pooled individual-level reanalysis of CORONA and GISSI-HF.
Feinstein MJ; Jhund P; Kang J; Ning H; Maggioni A; Wikstrand J; Kjekshus J; Tavazzi L; McMurray J; Lloyd-Jones DM
Eur J Heart Fail; 2015 Apr; 17(4):434-41. PubMed ID: 25684642
[TBL] [Abstract][Full Text] [Related]
9. Cancer in chronic heart failure patients in the GISSI-HF trial.
Ameri P; Canepa M; Luigi Nicolosi G; Marchioli R; Latini R; Tavazzi L; Maggioni AP;
Eur J Clin Invest; 2020 Sep; 50(9):e13273. PubMed ID: 32406516
[TBL] [Abstract][Full Text] [Related]
10. Low YKL-40 in chronic heart failure may predict beneficial effects of statins: analysis from the controlled rosuvastatin multinational trial in heart failure (CORONA).
Arain F; Gullestad L; Nymo S; Kjekshus J; Cleland JG; Michelsen A; McMurray JJ; Wikstrand J; Aukrust P; Ueland T
Biomarkers; 2017; 22(3-4):261-267. PubMed ID: 27325138
[TBL] [Abstract][Full Text] [Related]
11. Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial.
Maggioni AP; Fabbri G; Lucci D; Marchioli R; Franzosi MG; Latini R; Nicolosi GL; Porcu M; Cosmi F; Stefanelli S; Tognoni G; Tavazzi L;
Eur Heart J; 2009 Oct; 30(19):2327-36. PubMed ID: 19717850
[TBL] [Abstract][Full Text] [Related]
12. A prospective, randomized study: Evaluation of the effect of rosuvastatin in patients with chronic obstructive pulmonary disease and pulmonary hypertension.
Chogtu B; Kuriachan S; Magazine R; Shetty KR; Kamath A; George MM; Tripathy A; Kumar DM
Indian J Pharmacol; 2016; 48(5):503-508. PubMed ID: 27721534
[TBL] [Abstract][Full Text] [Related]
13. Osteoprotegerin predicts progression of chronic heart failure: results from CORONA.
Ueland T; Dahl CP; Kjekshus J; Hulthe J; Böhm M; Mach F; Goudev A; Lindberg M; Wikstrand J; Aukrust P; Gullestad L
Circ Heart Fail; 2011 Mar; 4(2):145-52. PubMed ID: 21216833
[TBL] [Abstract][Full Text] [Related]
14. Lipophilic Statin Versus Rosuvastatin (Hydrophilic) Treatment for Heart Failure: a Meta-Analysis and Adjusted Indirect Comparison of Randomised Trials.
Bonsu KO; Reidpath DD; Kadirvelu A
Cardiovasc Drugs Ther; 2016 Apr; 30(2):177-88. PubMed ID: 26780905
[TBL] [Abstract][Full Text] [Related]
15. CCL21 is associated with fatal outcomes in chronic heart failure: data from CORONA and GISSI-HF trials.
Ueland T; Nymo SH; Latini R; McMurray JJ; Kjekshus J; Yndestad A; Fucili A; Grosu A; Masson S; Maggioni AP; Gullestad L; Aukrust P; ;
Eur J Heart Fail; 2013 Jul; 15(7):747-55. PubMed ID: 23487539
[TBL] [Abstract][Full Text] [Related]
16. Novel extracellular matrix biomarkers as predictors of adverse outcome in chronic heart failure: association between biglycan and response to statin therapy in the CORONA trial.
Ueland T; Aukrust P; Nymo SH; Kjekshus J; McMurray JJ; Wikstrand J; Block D; Zaugg C; Gullestad L
J Card Fail; 2015 Feb; 21(2):153-9. PubMed ID: 25451704
[TBL] [Abstract][Full Text] [Related]
17. Effects of n-3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI-HF trial.
Ghio S; Scelsi L; Latini R; Masson S; Eleuteri E; Palvarini M; Vriz O; Pasotti M; Gorini M; Marchioli R; Maggioni A; Tavazzi L;
Eur J Heart Fail; 2010 Dec; 12(12):1345-53. PubMed ID: 20952767
[TBL] [Abstract][Full Text] [Related]
18. Circulating microRNA-132 levels improve risk prediction for heart failure hospitalization in patients with chronic heart failure.
Masson S; Batkai S; Beermann J; Bär C; Pfanne A; Thum S; Magnoli M; Balconi G; Nicolosi GL; Tavazzi L; Latini R; Thum T
Eur J Heart Fail; 2018 Jan; 20(1):78-85. PubMed ID: 29027324
[TBL] [Abstract][Full Text] [Related]
19. Effect of rosuvastatin on repeat heart failure hospitalizations: the CORONA Trial (Controlled Rosuvastatin Multinational Trial in Heart Failure).
Rogers JK; Jhund PS; Perez AC; Böhm M; Cleland JG; Gullestad L; Kjekshus J; van Veldhuisen DJ; Wikstrand J; Wedel H; McMurray JJ; Pocock SJ
JACC Heart Fail; 2014 Jun; 2(3):289-97. PubMed ID: 24952697
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics and outcomes of hospitalized heart failure patients with systolic dysfunction and chronic obstructive pulmonary disease: findings from OPTIMIZE-HF.
Mentz RJ; Fiuzat M; Wojdyla DM; Chiswell K; Gheorghiade M; Fonarow GC; O'Connor CM
Eur J Heart Fail; 2012 Apr; 14(4):395-403. PubMed ID: 22302663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
